Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in PD Patients With Motor Fluctuations March 2019

[Farooqji]

clinicaltrials.gov/ct2/show...

[park_bear]

"Inclusion Criteria:

Successfully completed Study IPX203-B16-02"

"About IPX203

IPX203 is an investigational extended-release oral capsule formulation of carbidopa and levodopa, being studied as a potential treatment for the symptoms of advanced Parkinson's disease. It is designed to have an onset of effect similar to IR CD-LD while providing a longer duration of effect compared to other oral levodopa products available."

[Farooqji in reply to park_bear]

Thanks for extracting the useful/relevant info from the link